AbbVie (NYSE:ABBV) Given Buy Rating at Guggenheim

AbbVie (NYSE:ABBV)‘s stock had its “buy” rating reiterated by stock analysts at Guggenheim in a research report issued to clients and investors on Friday, Benzinga reports. They presently have a $288.00 target price on the stock. Guggenheim’s price target points to a potential upside of 5.09% from the company’s previous close.

A number of other equities research analysts have also issued reports on the company. Argus raised their price target on AbbVie from $250.00 to $270.00 in a research note on Tuesday, August 4th. Sanford C. Bernstein reissued a “market perform” rating and set a $225.00 price target (up from $203.00) on shares of AbbVie in a research note on Tuesday, June 23rd. Oppenheimer raised their price target on AbbVie from $244.00 to $258.00 and gave the stock a “neutral” rating in a research note on Monday, August 3rd. Citigroup raised their price target on AbbVie from $230.00 to $260.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 15th. Finally, Wall Street Zen lowered AbbVie from a “strong-buy” rating to a “buy” rating in a research note on Sunday, July 5th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $277.18.

AbbVie Trading Down 2.5%

ABBV stock traded down $7.07 during trading on Friday, reaching $274.05. The stock had a trading volume of 2,791,656 shares, compared to its average volume of 6,394,758. AbbVie has a 52 week low of $190.75 and a 52 week high of $283.43. The stock’s 50 day moving average is $259.79 and its two-hundred day moving average is $237.39. The firm has a market cap of $484.19 billion, a PE ratio of 77.43, a PEG ratio of 1.26 and a beta of 0.24.

AbbVie (NYSE:ABBV) last posted its earnings results on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, beating analysts’ consensus estimates of $3.61 by $0.04. The company had revenue of $16.99 billion for the quarter, compared to the consensus estimate of $16.80 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%. AbbVie’s revenue was up 10.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, research analysts anticipate that AbbVie will post 13.94 EPS for the current year.

Insiders Place Their Bets

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of AbbVie stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the completion of the sale, the executive vice president owned 74,430 shares of the company’s stock, valued at approximately $18,607,500. The trade was a 30.53% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.06% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On AbbVie

Large investors have recently bought and sold shares of the company. First County Bank CT boosted its holdings in AbbVie by 0.4% in the third quarter. First County Bank CT now owns 14,671 shares of the company’s stock worth $3,838,000 after acquiring an additional 61 shares in the last quarter. Sage Capital Advisors llc increased its position in shares of AbbVie by 0.4% during the third quarter. Sage Capital Advisors llc now owns 23,552 shares of the company’s stock valued at $6,161,000 after acquiring an additional 96 shares during the last quarter. McGlone Suttner Wealth Management Inc. grew its position in shares of AbbVie by 0.6% during the 3rd quarter. McGlone Suttner Wealth Management Inc. now owns 12,230 shares of the company’s stock valued at $3,199,000 after acquiring an additional 70 shares during the period. Sivik Global Healthcare LLC increased its position in AbbVie by 46.7% in the third quarter. Sivik Global Healthcare LLC now owns 22,000 shares of the company’s stock worth $5,755,000 after buying an additional 7,000 shares during the last quarter. Finally, Compass Financial Group INC SD increased its position in AbbVie by 15.3% in the third quarter. Compass Financial Group INC SD now owns 1,648 shares of the company’s stock worth $431,000 after buying an additional 219 shares during the last quarter. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Fresh clinical and regulatory developments are strengthening AbbVie’s growth narrative. Phase 3 data for SKYRIZI and RINVOQ in Crohn’s disease, along with FDA Breakthrough Therapy Designations for temab-A in colorectal and lung cancer, could expand the company’s long-term commercial opportunities. Early obesity data also add potential upside to the pipeline. AbbVie Could Be 44% Below Fair Value on Fresh Pipeline Wins
• Positive Sentiment: Long-term data presented at ACG 2026 continue to support the durability and growth prospects of SKYRIZI and RINVOQ. Analysts expect the two therapies to offset part of Humira’s revenue erosion and drive third-quarter top-line growth. AbbVie Highlights Long-Term SKYRIZI and RINVOQ Data
• Positive Sentiment: Royal Bank of Canada reaffirmed its Outperform rating and assigned a $280 price target, indicating continued confidence in AbbVie’s earnings outlook despite limited near-term upside at current levels.
• Neutral Sentiment: Recent coverage highlights AbbVie as an attractive income stock after market weakness pushed its dividend yield higher. That may support defensive and income-oriented demand, though the yield increase also reflects recent selling pressure. High-Yield Dividend Stocks
• Negative Sentiment: At a lofty valuation following a substantial rally, investors may be taking profits while assessing whether SKYRIZI and RINVOQ can fully replace Humira sales. Rising competition in immunology and the stock’s limited analyst-implied upside are additional near-term headwinds. Will SKYRIZI and RINVOQ Drive AbbVie’s Top-Line Growth?

About AbbVie

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women’s health.

The company’s products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.